Clarity Pharmaceuticals (ASX: CU6) has begun its phase II diagnostic trial for patients with prostate cancer using its Copper-64 SAR-Bombesin product in imaging scans.
Recruitment complete for Clarity s PROPELLER prostate cancer diagnostic trial fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.
Share:
SYDNEY, Dec. 15, 2020 /PRNewswire/ Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed a capital raising of $25,000,410.
Dr Alan Taylor, Executive Chairman of Clarity Pharmaceuticals, commented, It has been a pivotal year for Clarity with numerous critical milestones achieved in the development of our main products, advancement of our platform, as well as accelerated corporate and strategic activities despite facing an unprecedented global environment. The money raised will enable us to keep the momentum from 2020 going and provide financial resources to progress the following important initiatives: